Expression of the Novel Cardiac Biomarkers sST2, GDF-15, suPAR, and H-FABP in HFpEF Patients Compared to ICM, DCM, and Controls
Authors:
- Peter JirakPJPeter Jirak
- Rudin PistulliRPRudin Pistulli
- Michael LichtenauerMichael Lichtenauer
- Bernhard WernlyBernhard Wernly
- Vera PaarVPVera Paar
- Lukas J. MotlochLukas J. Motloch
- Richard RezarRRRichard Rezar
- Christian JungCJChristian Jung
- Uta C. HoppeUHUta C. Hoppe
- P. Christian SchulzePSP. Christian Schulze
- Daniel KretzschmarDKDaniel Kretzschmar
- Rüdiger C. Braun-DullaeusRBRüdiger C. Braun-Dullaeus
Open Access
- 15 April 2020
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (4) , 1130
Abstract
Background: Heart failure with preserved ejection fraction (HFpEF) remains an ongoing therapeutic and diagnostic challenge to date. In this study we aimed for an analysis of the diagnostic potential of four novel cardiovascular biomarkers, GDF-15, H-FABP, sST2, and suPAR in HFpEF patients compared to controls as well as ICM, and DCM. Methods: In total, we included 252 stable outpatients and controls (77 DCM, 62 ICM, 18 HFpEF, and 95 controls) in the present study. All patients were in a non-decompensated state and on a stable treatment regimen. Serum samples were obtained and analyzed for GDF-15 (inflammation, remodeling), H-FABP (ischemia and subclinical ischemia), sST2 (inflammation, remodeling) and suPAR (inflammation, remodeling) by means of ELISA. Results: A significant elevation of GDF-15 was found for all heart failure entities compared to controls (p < 0.005). Similarly, H-FABP evidenced a significant elevation in all heart failure entities compared to the control group (p < 0.0001). Levels of sST2 were significantly elevated in ICM and DCM patients compared to the control group and HFpEF patients (p < 0.0001). Regarding suPAR, a significant elevation in ICM and DCM patients compared to the control group (p < 0.0001) and HFpEF patients (p < 0.01) was observed. An AUC analysis identified H-FABP (0.792, 95% CI 0.713–0.870) and GDF-15 (0.787, 95% CI 0.696–0.878) as paramount diagnostic biomarkers for HFpEF patients. Conclusion: Based on their differences in secretion patterns, novel cardiovascular biomarkers might represent a promising diagnostic tool for HFpEF in the future.Keywords
This publication has 35 references indexed in Scilit:
- Clinical relevance of sST2 in cardiac diseasesClinical Chemistry and Laboratory Medicine (CCLM), 2016
- Heart failure preserved ejection fraction (HFpEF): an integrated and strategic reviewHeart Failure Reviews, 2015
- GDF-15 as a Target and Biomarker for Diabetes and Cardiovascular Diseases: A Translational ProspectiveJournal of Diabetes Research, 2015
- Angiotensin–Neprilysin Inhibition versus Enalapril in Heart FailureNew England Journal of Medicine, 2014
- The pathophysiology of heart failure with preserved ejection fractionNature Reviews Cardiology, 2014
- A Novel Paradigm for Heart Failure With Preserved Ejection FractionJACC, 2013
- Growth differentiation factor 15 in cardiovascular diseases: from bench to bedsideBiomarkers, 2011
- suPAR: The Molecular Crystal BallDisease Markers, 2009
- IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling systemJournal of Clinical Investigation, 2007
- Heart-Type Fatty Acid-Binding Protein Is More Sensitive Than Troponin T to Detect the Ongoing Myocardial Damage in Chronic Heart Failure PatientsJournal of Cardiac Failure, 2007